Pathology: la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | ||||||||||||
| KCSG-BR15-10, 2019 | MONARCH 3, 2017 | MonarchE, 2021 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | MONALEESA-2, 2016 | MONARCH 2, 2020 | DAWNA-1, 2021 | PALOMA-3, 2016 | FLIPPER, 2021 | MONALEESA-7, 2018 | MONALEESA-3, 2018 | ||
| palbociclib plus endocrine therapy | 2 | T1 | T1 | |||||||||||
| palbociclib plus fulvestrant | 2 | T1 | T1 | |||||||||||
| palbociclib plus letrozole | 2 | T1 | T1 | |||||||||||
| abemaciclib plus endocrine therapy | 1 | T1 | ||||||||||||
| dalpiciclib plus fulvestrant | 1 | T1 | ||||||||||||
| abemaciclib plus fulvestrant | 1 | T1 | ||||||||||||
| ribociclib plus endocrine therapy | 1 | T1 | ||||||||||||
| ribociclib plus fulvestrant | 1 | T1 | ||||||||||||
| abemaciclib plus aromatase inhibitor | 1 | T1 | ||||||||||||
| ribociclib plus letrozole | 1 | T1 | ||||||||||||
| capecitabine | 0 | T0 | ||||||||||||
| endocrine therapy | 0 | T0 | T0 | T0 | ||||||||||
| fulvestrant | 0 | T0 | T0 | T0 | T0 | T0 | ||||||||
| aromatase inhibitor | 0 | T0 | ||||||||||||
| letrozole | 0 | T0 | T0 | T0 | ||||||||||